Medical Supplies Market Worth $248.03 Billion by 2031 - Exclusive Report by MarketsandMarkets

DELRAY BEACH, Fla., Sept. 8, 2026 /PRNewswire/ -- According to MarketsandMarkets, the Medical Supplies Market is projected to reach USD 248.03 billion by 2031 from USD 194.76 billion in 2026, at a

PR NewswireSep 8 22:30

Dow Drops 438 Points On Losses For Amgen, Salesforce Shares

This article was automatically generated by MarketWatch using technology from Automated Insights. The Dow Jones Industrial Average is declining Tuesday morning with shares of Amgen and Salesforce

MarketWatchSep 8 21:45

Johnson & Johnson To Present Data Across Its Neuropsychiatry Portfolio at 2026 Psych Congress Annual Meeting

Johnson & Johnson (NYSE:JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress

BenzingaSep 8 20:03

Day 2 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Two CAR-T therapies vie for basic medical insurance coverage as executives from multiple companies maintain on-site presence.

1. As the national reimbursement drug negotiations entered their second day, several innovative drugs and products with high clinical value were brought to the negotiating table; 2. In line with past practice, innovative drugs that are relatively more difficult to negotiate, such as anti-cancer medications and treatments for rare diseases, tend to be scheduled more intensively in the subsequent days. The lineup of participating companies suggests that this arrangement has largely been maintained.

cls.cnSep 7 07:53

On-the-ground report from Day 2 of the 2026 NRDL negotiations: Blockbuster oncology drugs, including CAR-T therapies and the world’s first bispecific antibody-drug conjugate (ADC), made their debut, while products covered by commercial insurance sought to

① On the second day of national reimbursement negotiations, the focus shifted to innovative oncology drugs, with nearly 20 companies—including Hengrui Medicine, Eli Lilly and Co, Novartis, and Innovent Biologics—participating in the morning session; ② In the afternoon, multinational pharmaceutical firms took center stage, with Merck & Co, Roche, and Johnson & Johnson successively entering negotiations as several blockbuster innovative drugs were brought to the table; ③ Companies such as Heyuan Biopharma and JW Therapeutics, which emerged as new entrants in commercial health insurance formularies last year, are once again attempting to break into the basic medical insurance scheme, marking the transition of dual-formulary alignment into the practical implementation phase.

cls.cnSep 6 15:29

Insider Trades: Nvidia, TSMC, and Johnson & Johnson Among Notable Names

Seeking AlphaSep 5 23:03